Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR), specifically regarding the vesting and subsequent lapse of conditional share options granted in 2009.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation events rather than operational financial performance.
Material Changes
The primary material event reported is the full lapse of the remaining 50% of share options granted in 2009 to Executive Directors and PDMRs. These options were subject to an Earnings Per Share (EPS) performance condition over a four-year period ending December 31, 2012. The company confirmed it did not achieve the required EPS performance condition, resulting in the options lapsing on March 1, 2013.
Outlook, Risks, and Unusual Items
Management Commentary: The Remuneration Committee confirmed the lapse of options due to the failure to meet the EPS performance target. This follows a previous lapse of the first 50% of the 2009 grant in February 2012.
Risks and Contingencies: The filing highlights the risk of executive compensation forfeiture tied to specific performance metrics. No other risks or unusual items are detailed in this specific notification.
Important Facts for Investors to Verify
- The specific EPS performance targets that were not met for the 2009-2012 period.
- The total number of lapsed options, which includes 79,375 Ordinary Shares/ADS for Executive Director Dr. M. Slaoui and varying amounts for other PDMRs.
- Whether similar performance conditions apply to other outstanding option grants or long-term incentive plans.
- The impact of these lapses on overall executive compensation costs and retention strategies.